Jhulia Caroline Nunes Leal da Mota

Ms. Jhulia Caroline Nunes Leal da Mota

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2024 in Nutrition
Verified
Journal Article
Closed access
LCLucas M. Carvalho
Lucas M. Carvalho
BCBeatriz G. Carvalho
Beatriz G. Carvalho
LSLeticia L. Souza
Leticia L. Souza
JMJhulia Caroline Nunes Leal da Mota
Jhulia Caroline Nunes Leal da Mota
ARAmanda Ribeiro
Amanda Ribeiro
CFCarolina Ferreira
Carolina Ferreira

3 July 2025 in Nutrition
Verified
Journal Article
Closed access
LCLucas M. Carvalho
Lucas M. Carvalho
JMJhulia Caroline Nunes Leal da Mota
Jhulia Caroline Nunes Leal da Mota
ARAmanda A. Ribeiro
Amanda A. Ribeiro
BCBeatriz G. Carvalho
Beatriz G. Carvalho
JMJ. Alfredo Martinez
J. Alfredo Martinez
CNCarolina F Nicoletti
Carolina F Nicoletti

7 October 2024 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
JMJhulia Caroline Nunes Leal da Mota
Jhulia Caroline Nunes Leal da Mota
LCLucas Carvalho
Lucas Carvalho
ARAmanda Ribeiro
Amanda Ribeiro
LSLeticia L Souza
Leticia L Souza
EBEduardo F Borba
Eduardo F Borba
CFCarolina Ferreira
Carolina Ferreira
Introduction: DNA hypomethylation in patients with systemic lupus erythematosus (SLE) has been recently documented in the literature. Low levels of DNA methylation have been observed globally and in genes associated with immune and inflammatory pathways in SLE’s CD4+T lymphocytes. Given that certain micronutrients can either donate methyl groups within one-carbon metabolism pathways or serve as cofactors for enzymes involved in the DNA methylation process, this randomised, double-blind, placebo-controlled trial aims to investigate whether a 3-month supplementation of folic acid and vitamin B 12 will modulate the DNA methylation profile in subcutaneous adipose tissue (primary outcome) of women with SLE and normal weight or excess body weight. As secondary objectives, we will assess gene expression, telomere length and phenotypic characteristics (ie, clinical parameters, body weight and composition, abdominal circumference, food intake and disordered eating attitude, physical activity, lipid profile, serum concentrations of leptin, adiponectin, and cytokines). Methods and analysis: Patients will be classified according to their nutritional status by body mass index in normal weight or excess body weight. Subsequently, patients in each group will be randomly assigned to either a placebo or an intervention group (folic acid (400 mcg) and vitamin B 12 (2000 mcg) supplementation). Endpoint evaluations will be conducted using both intention-to-treat and per-protocol analyses. This study has the potential to design new personalised nutritional approaches as adjunctive therapy for patients with SLE. Ethics and dissemination: This study has been reviewed and approved by the Ethical Committee from Clinical Hospital of the School of Medicine of the University of Sao Paulo, Brazil (CAAE.: 47317521.8.0000.0068). Trial registration number: NCT05097365 (first version).

20 March 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
LSLeticia L. Souza
Leticia L. Souza
JMJhulia Caroline Nunes Leal da Mota
Jhulia Caroline Nunes Leal da Mota
LCLucas Carvalho
Lucas Carvalho
ARAmanda Ribeiro
Amanda Ribeiro
CCCesar A. Caponi
Cesar A. Caponi
CNCarolina F Nicoletti
Carolina F Nicoletti
Objective: This in vitro study aimed to investigate the impact of folic acid on DNA methylation and gene expression in adipocytes from subcutaneous adipose tissue of patients with systemic lupus erythematosus (SLE), with a focus on the influence of obesity on these epigenetic changes. Methods: Tissue biopsies were collected from patients with normal weight (NW) and obesity (OBS). Adipocytes were isolated via enzymatic digestion and density separation. Each group was divided into control (standard medium) and folic acid treatment (2 mg/24 h for 48 h) conditions. After treatment, DNA methylation levels were analyzed using the Infinium Methylation EPIC v2.0 Kit, and gene expression analyses were performed by RT-qPCR. A pathway enrichment analysis was conducted using the KEGG database for functional insight. Results: Folic acid induced differential methylation at 755 CpG sites in NW adipocytes, which were associated with immune regulation, including MAPK signaling. Also, OBS adipocytes showed methylation changes at 92 CpG sites, affecting pathways related to metabolic regulation, such as cAMP signaling. LEP gene expression was upregulated (5.2-fold) in OBS adipocytes, while CREM2 expression was increased (2.8-fold) in NW adipocytes after treatment. These gene expression differences underscore weight-dependent responses to folic acid, with LEP upregulation in OBS cells suggesting links to metabolic dysregulation and CREM2 upregulation in NW cells potentially contributing to immune modulation. Conclusions: Folic acid treatment exerts distinct epigenetic and gene expression effects in adipocytes of SLE patients, modulated by obesity status. This weight-dependent response, marked by changes in pathways relevant to immune and metabolic function, highlights the need for further investigation into how nutrient-based interventions might support SLE management. From a clinical perspective, this study underscores the potential of targeted nutrient-based interventions to address immunometabolic dysfunctions in SLE patients. Further research could explore folic acid supplementation as a complementary approach to personalized treatment strategies, particularly for patients with obesity.

19 December 2023 in Journal of Public Health
Verified
Journal Article
Closed access
PDF file
JMJhulia Caroline Nunes Leal da Mota
Jhulia Caroline Nunes Leal da Mota
CFCarolina Ferreira
Carolina Ferreira
MMMatheus Molina Meletti
Matheus Molina Meletti
Igor LongobardiIgor Longobardi
Igor Longobardi
Hamilton RoschelHamilton Roschel
Hamilton Roschel
KGKarla Goessler
Karla Goessler

1 January 2026 in Genes
Verified
Journal Article
Open access
PDF file
Andrea Higuera GómezAndrea Higuera Gómez
Andrea Higuera Gómez
MMMaria Martinez-Urbistondo
Maria Martinez-Urbistondo
ACAmanda Cuevas-Sierra
Amanda Cuevas-Sierra
BCBegoña de Cuevillas
Begoña de Cuevillas
Ulises De la Cruz-MossoUlises De la Cruz-Mosso
Ulises De la Cruz-Mosso
JMJ. Alfredo Martinez
J. Alfredo Martinez
Background/Objectives: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a multifactorial origin involving genetic, epigenetic, and environmental determinants as well as some risk factors. Genetic predisposition has been quantified through polygenic risk scores (PRS), which integrate the cumulative effect of multiple single nucleotide variants (SNVs) associated with disease risk. Despite extensive research on immune and inflammatory pathways in SLE, the interplay between genetic susceptibility and metabolic dysfunction remains poorly understood. This study aimed to explore associations between SLE-related PRS and metabolic, inflammatory, and clinical parameters in adults participating in the METAINFLAMACIÓN-CM project (Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain). Methods: Ninety-three participants were included: 56 SLE patients and 37 individuals with metabolic syndrome (MetS) as a reference group. PRS were computed based on validated lupus-associated SNVs. Results: SLE patients showed a distinct metabolic profile compared with the MetS group, characterized by lower BMI, visceral fat, blood pressure, glucose, and liver enzyme levels. Within the SLE cohort, PRS values varied markedly and correlated with specific clinical and biochemical features. Linear regression models revealed a significant inverse association between PRS in SLE and ferritin levels, whereas other metabolic and inflammatory markers (glucose, IL-6, LDL, CRP, neutrophils) were directly influenced by clinical factors. Conclusions: Polygenic predisposition contributes to variability in SLE metabolic phenotype but does not independently drive most inflammatory parameters. SLE patients displayed metabolic and inflammatory alterations relevant to cardiovascular risk, highlighting the importance of comprehensive cardiometabolic assessment. Integrating PRS with metabolic profiling may support precision personalized management and improve cardiovascular risk evaluation in SLE.